

Reference:	FOI.19098.25
Subject:	Asthma
Date of Request:	12 December 2025

Requested:

1. How many new patients were treated for Asthma by the Trust’s Respiratory Department in the latest 4 month period (August - November 2025) with the treatments I have provided below?

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments either in or before March 2025, they can be classed as a new patient for the purposes of this question.

- Cinqaero (Reslizumab)
- Dupixent (Dupilumab)
- Fasentra (Benralizumab)
- Nucala (Mepolizumab)
- Tezpire (Tezepelumab)
- Xolair (Omalizumab)

2. How many new patients were treated for Chronic Obstructive Pulmonary Disease (COPD) by the Trust’s Respiratory Department in the latest 4-month period (August – November 2025) with the treatments I have provided below?

Please can you define a “new patient” as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments either in or before March 2025, they can be classed as a new patient for the purposes of this question.

- Dupixent (Dupilumab)
- Nucala (Mepolizumab)

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of new patients that have been treated for Asthma with the listed medications, by its Respiratory Department, during the period 1 August to 30 November 2025.

Please note: The UHB has defined a new patient as those patients who have not been issued with any of the listed medications during the period 1 August to 30 November 2025 and reflect each patient’s current treatment. Some patients may also be receiving these medications for non-respiratory indications.

Medication	Number
Cinqaero (Reslizumab)	0
Dupixent (Dupilumab)	*
Fasentra (Benralizumab)	*
Nucala (Mepolizumab)	0
Tezpire (Tezepelumab)	20
Xolair (Omalizumab)	*

Where the figures in the table above have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FOIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection (UK GDPR) Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. The UHB does not prescribe the medications listed for Chronic Obstructive Pulmonary Disease (COPD) as they are not currently approved by the National Institute for Health and Care Excellence (NICE) for this purpose.